JP2010539187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539187A5 JP2010539187A5 JP2010525103A JP2010525103A JP2010539187A5 JP 2010539187 A5 JP2010539187 A5 JP 2010539187A5 JP 2010525103 A JP2010525103 A JP 2010525103A JP 2010525103 A JP2010525103 A JP 2010525103A JP 2010539187 A5 JP2010539187 A5 JP 2010539187A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- dioxo
- dihydropyrimidin
- tert
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 45
- -1 hydroxy, methyl Chemical group 0.000 claims 39
- 150000003839 salts Chemical class 0.000 claims 39
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 239000003814 drug Substances 0.000 claims 32
- 125000003342 alkenyl group Chemical group 0.000 claims 30
- 125000000304 alkynyl group Chemical group 0.000 claims 27
- 125000005843 halogen group Chemical group 0.000 claims 23
- 241000711549 Hepacivirus C Species 0.000 claims 22
- 229940124597 therapeutic agent Drugs 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000004452 carbocyclyl group Chemical group 0.000 claims 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 13
- 125000004043 oxo group Chemical group O=* 0.000 claims 13
- 125000003302 alkenyloxy group Chemical group 0.000 claims 12
- 125000005133 alkynyloxy group Chemical group 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 9
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229960000329 ribavirin Drugs 0.000 claims 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 9
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 102000014150 Interferons Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 229920002477 rna polymer Polymers 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims 5
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 5
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 claims 5
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims 5
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims 5
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 5
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 5
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 claims 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 208000005176 Hepatitis C Diseases 0.000 claims 4
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 4
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 3
- 125000005087 alkynylcarbonyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 3
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 3
- 241001493065 dsRNA viruses Species 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- AQFWJMYYGAZRTL-UHFFFAOYSA-N 1-[3-(2-amino-1,3-benzothiazol-6-yl)-5-tert-butyl-4-methoxyphenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC(N)=NC3=CC=2)C=C1N1C=CC(=O)NC1=O AQFWJMYYGAZRTL-UHFFFAOYSA-N 0.000 claims 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 claims 2
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 claims 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000000845 uracil-1-yl group Chemical group [*]N1C(=O)N([H])C(=O)C([H])=C1[H] 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- YXRGAZPCDALZSP-UHFFFAOYSA-N 1-(3-tert-butyl-4-methoxy-5-naphthalen-2-ylphenyl)pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC=CC3=CC=2)C=C1N1C=CC(=O)NC1=O YXRGAZPCDALZSP-UHFFFAOYSA-N 0.000 claims 1
- XZXYGRARNRNIPW-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-2-yl)-5-tert-butyl-4-methoxyphenyl]-1,3-diazinane-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2SC3=CC=CC=C3N=2)C=C1N1CCC(=O)NC1=O XZXYGRARNRNIPW-UHFFFAOYSA-N 0.000 claims 1
- PVIVCOLZLYNGPB-UHFFFAOYSA-N 1-[3-(1,3-benzothiazol-6-yl)-5-tert-butyl-4-methoxyphenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC=NC3=CC=2)C=C1N1C=CC(=O)NC1=O PVIVCOLZLYNGPB-UHFFFAOYSA-N 0.000 claims 1
- JAESXJLAMBRTBM-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-(1-methylsulfonyl-2,3-dihydroindol-5-yl)phenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCN(C3=CC=2)S(C)(=O)=O)C=C1N1C=CC(=O)NC1=O JAESXJLAMBRTBM-UHFFFAOYSA-N 0.000 claims 1
- HHBKKXLZBBILEV-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-(1-oxo-2,3-dihydroinden-5-yl)phenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O HHBKKXLZBBILEV-UHFFFAOYSA-N 0.000 claims 1
- RWPKQMZFXORKQF-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-(1-oxo-2,3-dihydroisoindol-5-yl)phenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CNC(=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O RWPKQMZFXORKQF-UHFFFAOYSA-N 0.000 claims 1
- ZFRHKNRVKQELLK-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-(3-methyl-1-benzofuran-6-yl)phenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3OC=C(C)C3=CC=2)C=C1N1C=CC(=O)NC1=O ZFRHKNRVKQELLK-UHFFFAOYSA-N 0.000 claims 1
- XNJMOOOQQDDAAE-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-(5-nitro-1,3-benzoxazol-2-yl)phenyl]-1,3-diazinane-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2OC3=CC=C(C=C3N=2)[N+]([O-])=O)C=C1N1CCC(=O)NC1=O XNJMOOOQQDDAAE-UHFFFAOYSA-N 0.000 claims 1
- DHOPGXUASGTCKU-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-(6-methoxynaphthalen-2-yl)phenyl]pyrimidine-2,4-dione Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C(=C(C=1)C(C)(C)C)OC)=CC=1N1C=CC(=O)NC1=O DHOPGXUASGTCKU-UHFFFAOYSA-N 0.000 claims 1
- SAGLGVMHVLWDRP-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-(6-nitro-1,3-benzoxazol-2-yl)phenyl]-1,3-diazinane-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2OC3=CC(=CC=C3N=2)[N+]([O-])=O)C=C1N1CCC(=O)NC1=O SAGLGVMHVLWDRP-UHFFFAOYSA-N 0.000 claims 1
- NWHSVWGQIUBZQT-UHFFFAOYSA-N 1-[3-tert-butyl-4-methoxy-5-[2-(propylamino)-1,3-benzothiazol-6-yl]phenyl]pyrimidine-2,4-dione Chemical compound C1=C2SC(NCCC)=NC2=CC=C1C(C(=C(C=1)C(C)(C)C)OC)=CC=1N1C=CC(=O)NC1=O NWHSVWGQIUBZQT-UHFFFAOYSA-N 0.000 claims 1
- FBNXRQIJHASXJZ-UHFFFAOYSA-N 1-[3-tert-butyl-5-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-4-methoxyphenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(O)C3=CC=2)C=C1N1C=CC(=O)NC1=O FBNXRQIJHASXJZ-UHFFFAOYSA-N 0.000 claims 1
- WWCQVRQPZOUFOP-UHFFFAOYSA-N 1-[3-tert-butyl-5-(2-chloro-1,3-benzothiazol-6-yl)-4-methoxyphenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC(Cl)=NC3=CC=2)C=C1N1C=CC(=O)NC1=O WWCQVRQPZOUFOP-UHFFFAOYSA-N 0.000 claims 1
- DGTXGWLRWHJWAO-UHFFFAOYSA-N 1-[3-tert-butyl-5-[2-(2,5-dimethylpyrrol-1-yl)-1,3-benzothiazol-6-yl]-4-methoxyphenyl]pyrimidine-2,4-dione Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC(=NC3=CC=2)N2C(=CC=C2C)C)C=C1N1C=CC(=O)NC1=O DGTXGWLRWHJWAO-UHFFFAOYSA-N 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- MTNFZAKOJUMHNX-UHFFFAOYSA-N 2-[5-(2,4-dioxopyrimidin-1-yl)-3-[6-(methanesulfonamido)naphthalen-2-yl]-2-methoxyphenyl]-2-methylpropanoic acid Chemical compound C1=C(C(C)(C)C(O)=O)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O MTNFZAKOJUMHNX-UHFFFAOYSA-N 0.000 claims 1
- YNFBMDWHEHETJW-UHFFFAOYSA-N 2-pyridin-2-yl-1h-benzimidazole Chemical compound N1=CC=CC=C1C1=NC2=CC=CC=C2N1 YNFBMDWHEHETJW-UHFFFAOYSA-N 0.000 claims 1
- PCJMVHPWWFMSSS-UHFFFAOYSA-N 5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-n-methylsulfonyl-2,3-dihydro-1h-indene-1-carboxamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(C3=CC=2)C(=O)NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O PCJMVHPWWFMSSS-UHFFFAOYSA-N 0.000 claims 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 claims 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims 1
- YZDBZOOCRDOXFK-UHFFFAOYSA-N cyano-(diazidoamino)carbamic acid Chemical compound C(=O)(O)N(N(N=[N+]=[N-])N=[N+]=[N-])C#N YZDBZOOCRDOXFK-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 claims 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 125000005280 halo alkyl sulfonyloxy group Chemical group 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- UHMIQMCYZFEWKI-UHFFFAOYSA-N methyl 2-[5-(2,4-dioxopyrimidin-1-yl)-3-[6-(methanesulfonamido)naphthalen-2-yl]-2-methoxyphenyl]-2-methylpropanoate Chemical compound C=1C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)=C(OC)C(C(C)(C)C(=O)OC)=CC=1N1C=CC(=O)NC1=O UHMIQMCYZFEWKI-UHFFFAOYSA-N 0.000 claims 1
- LWUPFIBYTKEWJQ-UHFFFAOYSA-N n'-[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]methanesulfonohydrazide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(C3=CC=2)NNS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O LWUPFIBYTKEWJQ-UHFFFAOYSA-N 0.000 claims 1
- CMOBXBANKIGTSJ-UHFFFAOYSA-N n-(2-cyanophenyl)pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)NC1=CC=CC=C1C#N CMOBXBANKIGTSJ-UHFFFAOYSA-N 0.000 claims 1
- WUYINQBOZASLCM-UHFFFAOYSA-N n-(4-cyanophenyl)pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)NC1=CC=C(C#N)C=C1 WUYINQBOZASLCM-UHFFFAOYSA-N 0.000 claims 1
- BSGREXYSTRLYNX-SZXQPVLSSA-N n-[(e)-[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydroinden-1-ylidene]amino]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(/C3=CC=2)=N\NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O BSGREXYSTRLYNX-SZXQPVLSSA-N 0.000 claims 1
- WZXVXZFFDOBSBD-YYADALCUSA-N n-[(e)-[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)phenyl]-2,3-dihydroinden-1-ylidene]amino]methanesulfonamide Chemical compound C=1C(C(C)(C)C)=CC(C=2C=C3CCC(/C3=CC=2)=N\NS(C)(=O)=O)=CC=1N1C=CC(=O)NC1=O WZXVXZFFDOBSBD-YYADALCUSA-N 0.000 claims 1
- WTLGVHMLSDGNGC-SZXQPVLSSA-N n-[(e)-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-thiophen-2-ylphenyl]-2,3-dihydroinden-1-ylidene]amino]methanesulfonamide Chemical compound C1=C(C=2C=C3C(=N/NS(C)(=O)=O)/CCC3=CC=2)C(OC)=C(C=2SC=CC=2)C=C1N1C=CC(=O)NC1=O WTLGVHMLSDGNGC-SZXQPVLSSA-N 0.000 claims 1
- UZAAZICNWHJGFD-SZXQPVLSSA-N n-[(e)-[6-[5-(2,4-dioxopyrimidin-1-yl)-3-(furan-2-yl)-2-methoxyphenyl]-2,3-dihydroinden-1-ylidene]amino]methanesulfonamide Chemical compound C1=C(C=2C=C3C(=N/NS(C)(=O)=O)/CCC3=CC=2)C(OC)=C(C=2OC=CC=2)C=C1N1C=CC(=O)NC1=O UZAAZICNWHJGFD-SZXQPVLSSA-N 0.000 claims 1
- OIOOUZKXUXQCIF-JOCHJYFZSA-N n-[2-[(1r)-5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]propan-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CC[C@H](C3=CC=2)C(C)(C)NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O OIOOUZKXUXQCIF-JOCHJYFZSA-N 0.000 claims 1
- OIOOUZKXUXQCIF-QFIPXVFZSA-N n-[2-[(1s)-5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]propan-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CC[C@@H](C3=CC=2)C(C)(C)NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O OIOOUZKXUXQCIF-QFIPXVFZSA-N 0.000 claims 1
- FJGZPBUBGDMIEQ-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]-1,3-benzothiazol-5-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2SC3=CC=C(NS(C)(=O)=O)C=C3N=2)C=C1N1CCC(=O)NC1=O FJGZPBUBGDMIEQ-UHFFFAOYSA-N 0.000 claims 1
- DOARMVDILKEQDJ-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]-1,3-benzothiazol-6-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2SC3=CC(NS(C)(=O)=O)=CC=C3N=2)C=C1N1CCC(=O)NC1=O DOARMVDILKEQDJ-UHFFFAOYSA-N 0.000 claims 1
- GQSANLVBMNPJMC-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]-1,3-benzoxazol-5-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2OC3=CC=C(NS(C)(=O)=O)C=C3N=2)C=C1N1CCC(=O)NC1=O GQSANLVBMNPJMC-UHFFFAOYSA-N 0.000 claims 1
- MEZSDRNJRNOHMP-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]-1,3-benzoxazol-6-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2OC3=CC(NS(C)(=O)=O)=CC=C3N=2)C=C1N1CCC(=O)NC1=O MEZSDRNJRNOHMP-UHFFFAOYSA-N 0.000 claims 1
- KZJUZGIPMPKLQT-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]-3h-benzimidazol-5-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2NC3=CC=C(NS(C)(=O)=O)C=C3N=2)C=C1N1CCC(=O)NC1=O KZJUZGIPMPKLQT-UHFFFAOYSA-N 0.000 claims 1
- WXGACALVDQEAAO-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1,3-benzoxazol-5-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2OC3=CC=C(NS(C)(=O)=O)C=C3N=2)C=C1N1C=CC(=O)NC1=O WXGACALVDQEAAO-UHFFFAOYSA-N 0.000 claims 1
- YVFJERSHMIZROV-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-3,4-dihydro-1h-isoquinolin-6-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(N2CC3=CC=C(NS(C)(=O)=O)C=C3CC2)C=C1N1C=CC(=O)NC1=O YVFJERSHMIZROV-UHFFFAOYSA-N 0.000 claims 1
- XITJLAONOGOXPU-UHFFFAOYSA-N n-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]quinolin-6-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2N=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O XITJLAONOGOXPU-UHFFFAOYSA-N 0.000 claims 1
- OIOOUZKXUXQCIF-UHFFFAOYSA-N n-[2-[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]propan-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(C3=CC=2)C(C)(C)NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O OIOOUZKXUXQCIF-UHFFFAOYSA-N 0.000 claims 1
- SZESPTRIDHGUMG-UHFFFAOYSA-N n-[2-[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-3h-inden-1-yl]propan-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CC=C(C3=CC=2)C(C)(C)NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O SZESPTRIDHGUMG-UHFFFAOYSA-N 0.000 claims 1
- QFNWRWSMBBUABM-UHFFFAOYSA-N n-[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(C3=CC=2)NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O QFNWRWSMBBUABM-UHFFFAOYSA-N 0.000 claims 1
- ORZIFRIOPKCERB-UHFFFAOYSA-N n-[6-[3-(3-chlorophenyl)-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C=2C=C(Cl)C=CC=2)C=C1N1C=CC(=O)NC1=O ORZIFRIOPKCERB-UHFFFAOYSA-N 0.000 claims 1
- DONIOQPZCANINF-UHFFFAOYSA-N n-[6-[3-bromo-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(Br)C=C1N1C=CC(=O)NC1=O DONIOQPZCANINF-UHFFFAOYSA-N 0.000 claims 1
- DHPZPQJFXMGFMT-UHFFFAOYSA-N n-[6-[3-tert-butyl-2-chloro-5-(2,4-dioxopyrimidin-1-yl)phenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C=1C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)=C(Cl)C(C(C)(C)C)=CC=1N1C=CC(=O)NC1=O DHPZPQJFXMGFMT-UHFFFAOYSA-N 0.000 claims 1
- VTZYWEBKMIPMOK-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1CCC(=O)NC1=O VTZYWEBKMIPMOK-UHFFFAOYSA-N 0.000 claims 1
- YZNCUYVHKAAFNE-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-ethoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OCC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O YZNCUYVHKAAFNE-UHFFFAOYSA-N 0.000 claims 1
- VQTJHVDHKTWBNP-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1,3-benzothiazol-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC(NS(C)(=O)=O)=NC3=CC=2)C=C1N1C=CC(=O)NC1=O VQTJHVDHKTWBNP-UHFFFAOYSA-N 0.000 claims 1
- GQYTVPPMADGMEG-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-3,4-dihydro-1h-isoquinolin-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCN(CC3=CC=2)NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O GQYTVPPMADGMEG-UHFFFAOYSA-N 0.000 claims 1
- VHAQVZZQZQBPFL-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]quinolin-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=NC3=CC=2)C=C1N1C=CC(=O)NC1=O VHAQVZZQZQBPFL-UHFFFAOYSA-N 0.000 claims 1
- QIPZQFYINUXBFX-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]quinoxalin-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3N=CC(NS(C)(=O)=O)=NC3=CC=2)C=C1N1C=CC(=O)NC1=O QIPZQFYINUXBFX-UHFFFAOYSA-N 0.000 claims 1
- JAQQZCHPFDGGCY-UHFFFAOYSA-N n-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)phenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C=1C(C(C)(C)C)=CC(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)=CC=1N1C=CC(=O)NC1=O JAQQZCHPFDGGCY-UHFFFAOYSA-N 0.000 claims 1
- RQFNDCIXKAIMTO-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-(1-methoxy-2-methylpropan-2-yl)phenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C=1C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)=C(OC)C(C(C)(C)COC)=CC=1N1C=CC(=O)NC1=O RQFNDCIXKAIMTO-UHFFFAOYSA-N 0.000 claims 1
- BFSOPAVRUAFZES-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-(2-trimethylsilylethynyl)phenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C#C[Si](C)(C)C)C=C1N1C=CC(=O)NC1=O BFSOPAVRUAFZES-UHFFFAOYSA-N 0.000 claims 1
- JUEYZKZXMUYVJK-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-(5-methylfuran-2-yl)phenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C=2OC(C)=CC=2)C=C1N1C=CC(=O)NC1=O JUEYZKZXMUYVJK-UHFFFAOYSA-N 0.000 claims 1
- OHJVMZMYTGBOFZ-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-(trifluoromethyl)phenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C(F)(F)F)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O OHJVMZMYTGBOFZ-UHFFFAOYSA-N 0.000 claims 1
- MOXQSCXVOXWDML-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-phenylphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C=2C=CC=CC=2)C=C1N1C=CC(=O)NC1=O MOXQSCXVOXWDML-UHFFFAOYSA-N 0.000 claims 1
- PZUHHFOWCAQSSK-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-thiophen-2-ylphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C=2SC=CC=2)C=C1N1C=CC(=O)NC1=O PZUHHFOWCAQSSK-UHFFFAOYSA-N 0.000 claims 1
- HSWQYCLLXRZTNO-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-thiophen-3-ylphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C2=CSC=C2)C=C1N1C=CC(=O)NC1=O HSWQYCLLXRZTNO-UHFFFAOYSA-N 0.000 claims 1
- QNBYHXKNWCQTLS-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-3-(1-hydroxy-2-methylpropan-2-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)CO)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O QNBYHXKNWCQTLS-UHFFFAOYSA-N 0.000 claims 1
- MVWTZSAJNXJGAW-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-3-(furan-2-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C=2OC=CC=2)C=C1N1C=CC(=O)NC1=O MVWTZSAJNXJGAW-UHFFFAOYSA-N 0.000 claims 1
- IWCJOVAPXCYCKX-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-3-(furan-3-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(C2=COC=C2)C=C1N1C=CC(=O)NC1=O IWCJOVAPXCYCKX-UHFFFAOYSA-N 0.000 claims 1
- WTXZYCQMXHDUAC-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-3-(methanesulfonamido)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(NS(C)(=O)=O)C=C1N1C=CC(=O)NC1=O WTXZYCQMXHDUAC-UHFFFAOYSA-N 0.000 claims 1
- IWENBQYSPNHRJN-UHFFFAOYSA-N n-[6-[5-(2,4-dioxopyrimidin-1-yl)-3-iodo-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide Chemical compound C1=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C(OC)=C(I)C=C1N1C=CC(=O)NC1=O IWENBQYSPNHRJN-UHFFFAOYSA-N 0.000 claims 1
- DDQAGIWEIQNYDV-SANMLTNESA-N n-[[(1r)-5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-fluoro-2,3-dihydroinden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C([C@@](CC3)(F)CNS(C)(=O)=O)=CC=2)C=C1N1C=CC(=O)NC1=O DDQAGIWEIQNYDV-SANMLTNESA-N 0.000 claims 1
- IYTYOXLXXMKIMX-SFHVURJKSA-N n-[[(1r)-5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CC[C@@H](CNS(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O IYTYOXLXXMKIMX-SFHVURJKSA-N 0.000 claims 1
- DDQAGIWEIQNYDV-AREMUKBSSA-N n-[[(1s)-5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-fluoro-2,3-dihydroinden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C([C@](CC3)(F)CNS(C)(=O)=O)=CC=2)C=C1N1C=CC(=O)NC1=O DDQAGIWEIQNYDV-AREMUKBSSA-N 0.000 claims 1
- IYTYOXLXXMKIMX-GOSISDBHSA-N n-[[(1s)-5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CC[C@H](CNS(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O IYTYOXLXXMKIMX-GOSISDBHSA-N 0.000 claims 1
- DDQAGIWEIQNYDV-UHFFFAOYSA-N n-[[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-fluoro-2,3-dihydroinden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C(C(CC3)(F)CNS(C)(=O)=O)=CC=2)C=C1N1C=CC(=O)NC1=O DDQAGIWEIQNYDV-UHFFFAOYSA-N 0.000 claims 1
- SNZYDZSZLNFANX-UHFFFAOYSA-N n-[[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-methyl-2,3-dihydroinden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C(C(CC3)(C)CNS(C)(=O)=O)=CC=2)C=C1N1C=CC(=O)NC1=O SNZYDZSZLNFANX-UHFFFAOYSA-N 0.000 claims 1
- IYTYOXLXXMKIMX-UHFFFAOYSA-N n-[[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-2,3-dihydro-1h-inden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CCC(CNS(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O IYTYOXLXXMKIMX-UHFFFAOYSA-N 0.000 claims 1
- MNFQFJFIUOVKFY-UHFFFAOYSA-N n-[[5-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-3h-inden-1-yl]methyl]-n-methylmethanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3CC=C(CN(C)S(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O MNFQFJFIUOVKFY-UHFFFAOYSA-N 0.000 claims 1
- QEQINMWJWJSCMD-UHFFFAOYSA-N n-[[5-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-thiophen-2-ylphenyl]-3h-inden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C=2C=C3CC=C(CNS(C)(=O)=O)C3=CC=2)C(OC)=C(C=2SC=CC=2)C=C1N1C=CC(=O)NC1=O QEQINMWJWJSCMD-UHFFFAOYSA-N 0.000 claims 1
- DLRBINTUAXJWPN-UHFFFAOYSA-N n-[[5-[5-(2,4-dioxopyrimidin-1-yl)-2-methoxy-3-thiophen-3-ylphenyl]-3h-inden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C=2C=C3CC=C(CNS(C)(=O)=O)C3=CC=2)C(OC)=C(C2=CSC=C2)C=C1N1C=CC(=O)NC1=O DLRBINTUAXJWPN-UHFFFAOYSA-N 0.000 claims 1
- JKMROEKFKNRCQC-UHFFFAOYSA-N n-[[5-[5-(2,4-dioxopyrimidin-1-yl)-3-(furan-2-yl)-2-methoxyphenyl]-3h-inden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C=2C=C3CC=C(CNS(C)(=O)=O)C3=CC=2)C(OC)=C(C=2OC=CC=2)C=C1N1C=CC(=O)NC1=O JKMROEKFKNRCQC-UHFFFAOYSA-N 0.000 claims 1
- KSLSIEFZPSLNIF-UHFFFAOYSA-N n-[[5-[5-(2,4-dioxopyrimidin-1-yl)-3-(furan-3-yl)-2-methoxyphenyl]-3h-inden-1-yl]methyl]methanesulfonamide Chemical compound C1=C(C=2C=C3CC=C(CNS(C)(=O)=O)C3=CC=2)C(OC)=C(C2=COC=C2)C=C1N1C=CC(=O)NC1=O KSLSIEFZPSLNIF-UHFFFAOYSA-N 0.000 claims 1
- OHYYUFSMPNNOPR-UHFFFAOYSA-N n-[[6-[3-tert-butyl-2-chloro-5-(2,4-dioxopyrimidin-1-yl)phenyl]-1-benzothiophen-3-yl]methyl]methanesulfonamide Chemical compound C=1C(C=2C=C3SC=C(CNS(C)(=O)=O)C3=CC=2)=C(Cl)C(C(C)(C)C)=CC=1N1C=CC(=O)NC1=O OHYYUFSMPNNOPR-UHFFFAOYSA-N 0.000 claims 1
- AGGBXQKHIOJSOM-UHFFFAOYSA-N n-[[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1,2-benzoxazol-3-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3ON=C(CNS(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O AGGBXQKHIOJSOM-UHFFFAOYSA-N 0.000 claims 1
- DSBZMFBIBUTQAU-UHFFFAOYSA-N n-[[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-benzofuran-3-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3OC=C(CNS(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O DSBZMFBIBUTQAU-UHFFFAOYSA-N 0.000 claims 1
- NWDQPWDUNFAXND-UHFFFAOYSA-N n-[[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-benzothiophen-2-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC(CNS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NWDQPWDUNFAXND-UHFFFAOYSA-N 0.000 claims 1
- WFDAWIPJPPHQTK-UHFFFAOYSA-N n-[[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-benzothiophen-3-yl]methyl]-n-methylmethanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC=C(CN(C)S(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O WFDAWIPJPPHQTK-UHFFFAOYSA-N 0.000 claims 1
- CNFBZBKPLGSFTC-UHFFFAOYSA-N n-[[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]-1-benzothiophen-3-yl]methyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3SC=C(CNS(C)(=O)=O)C3=CC=2)C=C1N1C=CC(=O)NC1=O CNFBZBKPLGSFTC-UHFFFAOYSA-N 0.000 claims 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 claims 1
- ICTGBOFCIDHVPA-UHFFFAOYSA-N n-methylsulfonylmethanesulfonamide Chemical compound CS(=O)(=O)NS(C)(=O)=O ICTGBOFCIDHVPA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 229960003540 oxyquinoline Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97288107P | 2007-09-17 | 2007-09-17 | |
| US60/972,881 | 2007-09-17 | ||
| US9679208P | 2008-09-13 | 2008-09-13 | |
| US61/096,792 | 2008-09-13 | ||
| PCT/US2008/076592 WO2009039134A1 (en) | 2007-09-17 | 2008-09-17 | Anti-infective pyrimidines and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012221886A Division JP5931683B2 (ja) | 2007-09-17 | 2012-10-04 | 抗感染症ピリミジンおよびその使用 |
| JP2015082240A Division JP2015187106A (ja) | 2007-09-17 | 2015-04-14 | 抗感染症ピリミジンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539187A JP2010539187A (ja) | 2010-12-16 |
| JP2010539187A5 true JP2010539187A5 (enExample) | 2013-08-15 |
| JP5734655B2 JP5734655B2 (ja) | 2015-06-17 |
Family
ID=40308557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525103A Active JP5734655B2 (ja) | 2007-09-17 | 2008-09-17 | 抗感染症ピリミジンおよびその使用 |
| JP2012221886A Expired - Fee Related JP5931683B2 (ja) | 2007-09-17 | 2012-10-04 | 抗感染症ピリミジンおよびその使用 |
| JP2015082240A Pending JP2015187106A (ja) | 2007-09-17 | 2015-04-14 | 抗感染症ピリミジンおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012221886A Expired - Fee Related JP5931683B2 (ja) | 2007-09-17 | 2012-10-04 | 抗感染症ピリミジンおよびその使用 |
| JP2015082240A Pending JP2015187106A (ja) | 2007-09-17 | 2015-04-14 | 抗感染症ピリミジンおよびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8188104B2 (enExample) |
| EP (3) | EP2203431B1 (enExample) |
| JP (3) | JP5734655B2 (enExample) |
| CN (4) | CN104628655A (enExample) |
| AT (1) | ATE519746T1 (enExample) |
| CA (2) | CA2849420C (enExample) |
| CY (3) | CY1115514T1 (enExample) |
| DK (3) | DK2639226T3 (enExample) |
| ES (3) | ES2523864T3 (enExample) |
| HR (2) | HRP20110809T1 (enExample) |
| HU (1) | HUS1500013I1 (enExample) |
| LT (1) | LTC2203431I2 (enExample) |
| LU (1) | LU92666I2 (enExample) |
| MX (1) | MX2010002902A (enExample) |
| NL (1) | NL300729I2 (enExample) |
| NO (1) | NO2015011I1 (enExample) |
| PL (3) | PL2639226T3 (enExample) |
| PT (3) | PT2203431E (enExample) |
| RU (2) | RU2539570C2 (enExample) |
| SI (2) | SI2203431T1 (enExample) |
| WO (1) | WO2009039134A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101918369B (zh) | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| TWI534137B (zh) * | 2007-09-17 | 2016-05-21 | 艾伯維巴哈馬有限公司 | 抗感染劑及其用途 |
| PT2203431E (pt) * | 2007-09-17 | 2011-10-12 | Abbott Lab | Pirimidinas anti-infecciosas e seus usos |
| BRPI0916233A2 (pt) * | 2008-07-23 | 2018-03-13 | F.Hoffman-La Roche Ag | compostos heterocíclicos antivirais |
| KR20110061640A (ko) | 2008-09-26 | 2011-06-09 | 에프. 호프만-라 로슈 아게 | Ｈｃｖ 치료용 피린 또는 피라진 유도체 |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| CA2755023C (en) * | 2009-03-25 | 2016-12-13 | Abbott Laboratories | Antiviral compounds and uses thereof |
| CA2758838A1 (en) | 2009-04-25 | 2010-10-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| AR077004A1 (es) | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| SG176976A1 (en) | 2009-06-24 | 2012-02-28 | Hoffmann La Roche | Heterocyclic antiviral compound |
| AU2010297290A1 (en) | 2009-09-21 | 2012-03-15 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| EP2480528B1 (en) | 2009-09-25 | 2018-08-29 | Oryzon Genomics, S.A. | Lysine specific demethylase-1 inhibitors and their use |
| WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| KR20120085918A (ko) * | 2009-11-21 | 2012-08-01 | 에프. 호프만-라 로슈 아게 | 헤테로환형 항바이러스성 화합물 |
| TW201144298A (en) * | 2009-12-14 | 2011-12-16 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| US9062015B2 (en) * | 2009-12-14 | 2015-06-23 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| US8722743B2 (en) | 2010-04-19 | 2014-05-13 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| WO2012009698A1 (en) | 2010-07-16 | 2012-01-19 | Abbott Laboratories | Phosphine ligands for catalytic reactions |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| EA028082B1 (ru) | 2010-07-16 | 2017-10-31 | ЭббВи Айэленд Анлимитед Компани | Способ получения сульфонамидного противовирусного соединения |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| ES2674747T3 (es) | 2010-07-29 | 2018-07-03 | Oryzon Genomics, S.A. | Inhibidores de demetilasa LSD1 basados en arilciclopropilamina y sus usos médicos |
| WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) * | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| JP6046154B2 (ja) | 2011-10-20 | 2016-12-14 | オリソン ヘノミクス エセ． アー． | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
| BR112014006314A2 (pt) | 2011-10-21 | 2017-04-11 | Abbvie Inc | métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon |
| PT107925A (pt) * | 2011-10-21 | 2014-12-03 | Abbvie Inc | Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CN104884440A (zh) | 2012-08-21 | 2015-09-02 | 艾伯维公司 | 用于制备抗病毒化合物的方法 |
| WO2014063101A1 (en) | 2012-10-18 | 2014-04-24 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| MX394813B (es) * | 2016-03-17 | 2025-03-24 | Fmc Agro Singapore Pte Ltd | Proceso para convertir s-enantiómero a su forma racémica. |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN108290844B (zh) * | 2016-05-27 | 2021-04-30 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的萘环化合物及药物组合物及其应用 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN117466847A (zh) * | 2022-07-22 | 2024-01-30 | 中国医药工业研究总院有限公司 | 一种利非斯特中间体苯并呋喃-6-羧酸的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5162326A (en) * | 1990-02-15 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
| NL9001075A (enExample) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| SI1237878T1 (sl) | 1999-12-06 | 2007-08-31 | Hoffmann La Roche | 4-pirimidinil-n-acil-l-fenilanin |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| IL141034A0 (en) * | 2000-02-04 | 2002-02-10 | Sumitomo Chemical Co | Uracil compounds and use thereof |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| MXPA04007876A (es) * | 2002-02-14 | 2005-06-20 | Pharmasset Ltd | Analogos de nucleosido fluorado modificados. |
| MXPA05005547A (es) * | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7511145B2 (en) * | 2003-08-01 | 2009-03-31 | Genelabs Technologies, Inc. | Bicyclic heteroaryl derivatives |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| AU2005275181A1 (en) * | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1953147A1 (en) * | 2005-11-21 | 2008-08-06 | Japan Tobacco, Inc. | Heterocyclic compound and medicinal application thereof |
| TWI534137B (zh) * | 2007-09-17 | 2016-05-21 | 艾伯維巴哈馬有限公司 | 抗感染劑及其用途 |
| CN101918369B (zh) | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| PT2203431E (pt) | 2007-09-17 | 2011-10-12 | Abbott Lab | Pirimidinas anti-infecciosas e seus usos |
| BRPI0916233A2 (pt) | 2008-07-23 | 2018-03-13 | F.Hoffman-La Roche Ag | compostos heterocíclicos antivirais |
-
2008
- 2008-09-17 PT PT08832330T patent/PT2203431E/pt unknown
- 2008-09-17 PL PL12182277T patent/PL2639226T3/pl unknown
- 2008-09-17 ES ES11171399.6T patent/ES2523864T3/es active Active
- 2008-09-17 CN CN201410659529.4A patent/CN104628655A/zh active Pending
- 2008-09-17 PT PT121822779T patent/PT2639226T/pt unknown
- 2008-09-17 PT PT11171399T patent/PT2368882E/pt unknown
- 2008-09-17 PL PL08832330T patent/PL2203431T3/pl unknown
- 2008-09-17 AT AT08832330T patent/ATE519746T1/de active
- 2008-09-17 CN CN201210167588.0A patent/CN102746240B/zh not_active Expired - Fee Related
- 2008-09-17 CA CA2849420A patent/CA2849420C/en active Active
- 2008-09-17 DK DK12182277.9T patent/DK2639226T3/en active
- 2008-09-17 EP EP20080832330 patent/EP2203431B1/en active Active
- 2008-09-17 HR HR20110809T patent/HRP20110809T1/hr unknown
- 2008-09-17 DK DK11171399T patent/DK2368882T3/en active
- 2008-09-17 RU RU2010114827/04A patent/RU2539570C2/ru active
- 2008-09-17 WO PCT/US2008/076592 patent/WO2009039134A1/en not_active Ceased
- 2008-09-17 ES ES12182277.9T patent/ES2592961T3/es active Active
- 2008-09-17 PL PL11171399T patent/PL2368882T3/pl unknown
- 2008-09-17 EP EP12182277.9A patent/EP2639226B1/en not_active Not-in-force
- 2008-09-17 ES ES08832330T patent/ES2368879T3/es active Active
- 2008-09-17 DK DK08832330T patent/DK2203431T3/da active
- 2008-09-17 CN CN201410657922.XA patent/CN104628654A/zh active Pending
- 2008-09-17 EP EP20110171399 patent/EP2368882B1/en not_active Not-in-force
- 2008-09-17 JP JP2010525103A patent/JP5734655B2/ja active Active
- 2008-09-17 CN CN200880113534.8A patent/CN101842360B/zh active Active
- 2008-09-17 CA CA2699986A patent/CA2699986C/en not_active Expired - Fee Related
- 2008-09-17 RU RU2014147354/04A patent/RU2014147354A/ru not_active Application Discontinuation
- 2008-09-17 US US12/212,323 patent/US8188104B2/en active Active
- 2008-09-17 SI SI200830433T patent/SI2203431T1/sl unknown
- 2008-09-17 MX MX2010002902A patent/MX2010002902A/es active IP Right Grant
- 2008-09-17 SI SI200831329T patent/SI2368882T1/sl unknown
-
2011
- 2011-11-03 CY CY20111101065T patent/CY1115514T1/el unknown
-
2012
- 2012-04-20 US US13/451,889 patent/US8501238B2/en active Active
- 2012-10-04 JP JP2012221886A patent/JP5931683B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/838,223 patent/US9139536B2/en active Active
-
2014
- 2014-11-12 CY CY20141100943T patent/CY1115893T1/el unknown
- 2014-11-12 HR HRP20141102 patent/HRP20141102T1/hr unknown
-
2015
- 2015-02-25 LU LU92666C patent/LU92666I2/xx unknown
- 2015-03-04 LT LTPA2015013C patent/LTC2203431I2/lt unknown
- 2015-03-17 HU HUS1500013C patent/HUS1500013I1/hu unknown
- 2015-03-26 CY CY2015013C patent/CY2015013I1/el unknown
- 2015-04-08 NL NL300729C patent/NL300729I2/nl unknown
- 2015-04-14 JP JP2015082240A patent/JP2015187106A/ja active Pending
- 2015-04-22 NO NO2015011C patent/NO2015011I1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539187A5 (enExample) | ||
| HRP20110809T1 (hr) | Protuupalni pirimidini i njihove uporabe | |
| RU2013104270A (ru) | Производные урацила или тимина для лечения гепатита с | |
| JP2010539188A5 (enExample) | ||
| JP2010539186A5 (enExample) | ||
| JP5726527B2 (ja) | Ｃ型肝炎ウイルス（ｈｃｖ）阻害薬として有用なｎ−フェニル−ジオキソ−ヒドロピリミジン | |
| RU2015144653A (ru) | Противовирусные соединения и их применения | |
| JP2015526441A5 (enExample) | ||
| JP2007516173A5 (enExample) | ||
| JP2013505949A5 (enExample) | ||
| JP2006516626A5 (enExample) | ||
| JP2019516677A5 (enExample) | ||
| AU2014280939B2 (en) | Uracil or thymine derivative for treating hepatitis C |